Camilla Soenderby

Camilla Soenderby has been a Director at F2G since 2020. Prior to that, they were with Affibody AB and Takeda. Camilla has also served as an Industrial Advisor with EQT Partners/EQT AB.

Soenderby began their career with Shire in January 2018 as SVP, Head of Global Product Strategy. In January 2019, they joined Takeda as Chief Patient Value & Product Strategy Officer. In this role, they reported to the CEO and led the establishment of a global function that comprised Global Commercial Strategy, Global Market Access & Pricing, Global Commercial Excellence, and Global Patient Advocacy. Camilla also led a large portfolio of global brands with more than US$ 13 Bn in sales and a broad pipeline with cross functional teams based in Boston and Zurich.

Soenderby is a member of the Takeda Executive Team, the Business Review Committee and the Risk, Ethics & Compliance Committee, and executive sponsor for a cross company initiative to accelerate diagnosis of rare diseases using digital technology incl. AI.

Camilla Soenderby has a degree from the University of St. Gallen in Switzerland and a degree from the University of Copenhagen in Denmark.